ScinoPharm Taiwan, Ltd. and TaiGen Biotechnology, a pharmaceutical company based in Taipei, Taiwan, have signed a manufacturing contract for the clinical supply of the active pharmaceutical ingredient (API) for burixafor, a new chemical entity discovered and developed by TaiGen. The API will be manufactured in ScinoPharm's plant in Changshu, China.

Burixafor is a stem-cell mobilizer that can efficiently mobilize bone marrow stem cells and tissue precursor cells to the peripheral blood. It can be used in hematopoietic stem-cell transplantation, chemotherapy sensitization, and other ischemic diseases. The results of the ongoing Phase II clinical trial in the United States are very impressive. The drug has received a clinical trial application from China's FDA for the initiation of a Phase II clinical trial in chemotherapy sensitization under the 1.1 category.

Founded in 2001, TaiGen Biotechnology is  a research-based and product-driven pharmaceutical company engaging in the development of novel therapeutics for infectious diseases, cancer and diabetes-related complications

Source: ScinoPharm